Breast Cancer Prognosis in Young BRCA1/BRCA2 Mutation Carriers: A Retrospective Hospital-based Cohort Study

Area of Science:

• Oncology
• Genetics
• Clinical Research

Background:

• Conflicting results exist regarding the prognostic impact of germline BRCA1/2 mutations (gBRCAm) in breast cancer patients.
• Early-onset breast cancer (<30 years) warrants specific investigation due to potential genetic influences.

Purpose of the Study:

• To investigate the outcomes of breast cancer patients with gBRCA mutations and early onset compared to non-carriers.
• To clarify the prognostic significance of gBRCA1/2 mutations in a young patient cohort.

Main Methods:

• Retrospective study of 149 early-onset breast cancer patients (2005-2019).
• Evaluation of overall survival (OS) and disease-free survival (DFS).
• Hazard ratios (HR) calculated using Cox proportional hazards model.

Main Results:

• 18.8% of patients were gBRCAm carriers.
• No significant difference in OS between carriers and non-carriers (HR=1.90, p=0.22) after multivariable analysis.
• No significant difference in DFS between carriers and non-carriers (HR=1.39, p=0.42).

Conclusions:

• No clear evidence suggests gBRCA1/2 mutations significantly affect OS in very early-onset breast cancer patients.
• Findings indicate that gBRCAm status may not be a primary prognostic factor for survival in this specific population.
• Further research may be needed to explore other factors influencing outcomes in young breast cancer patients with gBRCA mutations.